9288.5000 161.50 (1.77%)
NSE Jul 09, 2025 15:31 PM
Volume: 37,170
 

9288.50
1.77%
Business Standard
AstraZeneca is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine using a lower dosage amid questions over the results from its late-stage study
More from AstraZeneca Pharma India Ltd.
Recommended